Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole |
| |
| Authors: | George R. Thompson Suffix" >III,Nathan P. Wiederhold |
| |
| Affiliation: | (1) Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California, Davis, 1 Shields Avenue, Tupper Hall, Rm. 3146, Davis, CA, 95616, USA;(2) Department of Internal Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, MSC 7881, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA;(3) University of Texas at Austin College of Pharmacy, 1 University Station, A1900, Austin, TX 78712, USA;(4) Pharmacotherapy Education and Research Center, University of Texas Health Science Center at San Antonio, MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78299, USA;(5) Department of Internal Medicine Divisions of Infectious Diseases, University of California, Davis, Davis, CA 95616, USA |
| |
| Abstract: | Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug–drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
